Eli Lilly (LLY) reached a key supply milestone Tuesday, announcing the launch of single-dose vials of Zepbound, one of the ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Last year, Lilly debuted the single-dose Zepbound vials at $399 for the 2.5 mg dose and $549 in its 5 mg dose strength, making the new prices $50 cheaper. The prices are for patients who pay for ...

The pharmaceutical giant announced in August it was offering 2.5 mg and 5 mg single-dose vials of tirzepatide for the first time in response to growing demand. At the time, Lilly said the doses ...

Eli Lilly on Tuesday released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the newly introduced Zepbound Self Pay Journey Program. The company said ...

(Image Credits: Pexels) Eli Lilly and Company (India) on Thursday announced the launch of Mounjaro in single-dose vial presentation following the marketing authorization from the Central Drugs ...